PPLPHARMA211.99

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹28,134 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.150.271.401.93
Interest Burden (Pretax/EBIT) ×0.260.54-2.58-1.07
EBIT Margin %5.586.871.021.66
Asset Turnover ×0.530.580.490.49
Financial Leverage (Assets/Equity) ×1.941.932.202.20
ROE (5-step product) %0.221.11-3.96-3.67
ROE (reported, avg-equity basis) %0.231.12-3.99-3.99
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.